Acetaminophen hepatoxicity: What do we know, what don't we know, and what do we do next?

Hepatology

Volumn 40, Issue 1, 2004, Pages 23-26

  Kaplowitz, Neil ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTATHIONE; PARACETAMOL; REACTIVE OXYGEN METABOLITE;

BIOENERGY; COVALENT BOND; DRUG OVERDOSE; EDITORIAL; HUMAN; IMMUNE SYSTEM; LIVER FAILURE; LIVER INJURY; LIVER TOXICITY; OXIDATIVE STRESS; PRESCRIPTION; PRIORITY JOURNAL;

ACETAMINOPHEN; ANALGESICS, NON-NARCOTIC; ANIMALS; HUMANS; LIVER;

EID: 3042826208     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20312     Document Type: Editorial

References (27)

1. Nelson SD, Bruschi SA. Mechanisms of acetaminophen-induced liver disease. In: Kaplowitz N, DeLeve L, eds. Drug-Induced Liver Disease. New York:Marcel Dekker Inc.; 2002287-325.
2. Watkins P. The role of cytochrome P450s in drug-induced liver disease, In: Kaplowitz N, DeLeve L, eds. Drug-Induced Liver Disease. New York: Marcel Dekker Inc., 2002:15-33.
3. Lee WM. Acetaminophen and the U.S. acute liver failure study group: lowering the risks of hepatic failure. HEPATOLOGY 2004;40:6-9.
4. James RC, Wessinger WD, Roberts SM, Millner GC, Paule MG. Centrally mediated opioid induced depression of hepatic glutathione: effects of intracerebroventricular administration of mu, kappa, sigma and delta agonists. Toxicology 1988;51:267-279.
5. Muldrew KL, James LP, Coop L, McCullough SS, Hendrickson HP, Hinson JA, et al. Determination of acetaminophen-protein adducts in mouse liver and serum and human serum after hepatotoxic doses of acetaminophen using high-performance liquid chromatography with electrochemical detection. Drug Metab Dispos 2002;30:446-451.
6. Rumack BH. Acetaminophen misconceptions. HEPATOLOGY 2004;40: 10-15.
7. Kaplowitz N. Causality assessment versus guilt-by-association in drug hepatotoxicity. HEPATOLOGY 2001;33:308-310.
8. Shayiq RM, Roberts DW, Rothstein K, Snawder JE, Benson W, Ma X, et al. Repeat exposure to incremental doses of acetaminophen provides protection against acetaminophen-induced lethality in mice: an explanation for high acetaminophen dosage in humans without hepatic injury. HEPATOLOGY 1999;29:451-463.
9. Zhang J, Huang W, Chua SS, Wei P, Moore DD. Modulation of acetaminophen-induced hepatotoxicity by the xenobiotic receptor CAR. Science 2002;298:421-424.
10. Chan K, Han X-D, Kan YW. An important function of Nrf2 in combating oxidative stress: detoxification of acetaminophen. Proc Natl Acad Sci U S A 2001;98:4611-4616.
11. Faich GA and Moseley RH. Troglitazone (Rezulin) and hepatic injury. Pharmacoepidemiol Drug Saf 2001;10:537-547.
12. Henderson CJ, Wolf CR, Kitteringham N, Powell H, Otto D, Park B, et al. Increased resistance to acetaminophen hepatotoxicity in mice lacking glutathione S-transferase Pi. Proc Natl Acad Sci U S A 2000;97:12741-12745.
13. Lee SS, Buters JT, Pineau T, Fernando-Salguero P, Gonzalez FJ. Role of CYP2E1 in the hepatotoxicity of acetaminophen. J Biol Chem 1996;271: 12063-12067.
14. Ishida Y, Kondo T, Ohsima T, Fujiwara H, Iwakura Y, Mukaida N, et al. A pivotal involvement of IFN-gamma in the pathogenesis of acetaminophen-induced acute liver injury. FASEB J 2002;16:1227-1236.
15. Liu Z-X, Kaplowitz N. Innate immune system determines acetaminophen (APAP) hepatotoxicity [abstract]. HEPATOLOGY 2003;38(Suppl):250A.
16. Zhang H, Cook J, Nickel J, Yu R, Stecker K, Myers K, et al. Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis. Nat Biotechnol 2000;18:862-867.
17. Bone-Larson CL, Hogaboam CM, Evanhoff H, Streiter RM, Kunkel SL. IFN-gamma-inducible protein-10 (CXCL10) is hepatoprotective during acute liver injury through the induction of CXCR2 on hepatocytes. J Immunol 2001;167:7077-7083.
18. Hogaboam CM, Bone-Larson CL, Steinhauser ML, Lukacs NW, Colletti LM, Simpson KJ, et al. Novel CXCR2-dependent liver regenerative qualities of ELR-containing CXC chemokines. FASEB J 1999;13: 1565-1574.
19. Masubuchi Y, Bourdi M, Reilly TP, Graf ML, George JW, Pohl LR. Role of interleukin-6 in hepatic heat shock protein expression and protection against acetaminophen-induced liver disease. Biochem Biophys Res Commun 2003;304:207-212.
20. Trepicchio WL, Bozza M, Bouchard P, Dorner AJ. Protective effect of rhIL-11 in a murine model of acetaminophen-induced hepatotoxicity. Toxicol Pathol 2001;29:242-249.
21. Jollow DJ, Mitchell JR, Potter WZ, Davis DC, Gillette JR, Brodie BB. Acetaminophen-induced hepatic necrosis. II. Role of covalent binding in vivo. J Pharmacol Exp Ther 1973;187:195-202.
22. Bourdi M, Masubuchi Y, Reilly TP, Amouzadeh HR, Martin JL, George JW, et al. Protection against acetaminophen-induced liver injury and lethality by interleukin 10: role of inducible nitric oxide synthase. HEPATOLOGY 2002;35:289-298.
23. Reilly TP, Brady JN, Marchick MR, Bourdi M, George JW, Radonovish MF, et al. A protective role for cyclooxygenase-2 in drug-induced liver injury in mice. Chem Res Toxicol 2001;14:1620-1628.
24. Ju C, Reilly TP, Bourdi M, Radonovich MF, Brady JN, George JW, et al. Protective role of Kupffer cells in acetaminophen-induced hepatic injury in mice. Chem Res Toxicol 2002;15:1504-1513.
25. Hogaboam CM, Bone-Larson CL, Steinhauser ML, Matsukawa A, Gosling J, Boring L, et al. Exaggerated hepatic injury due to acetaminophen challenge in mice lacking C-C chemokine receptor 2. Am J Pathol 2000; 156:1245-1252.
26. Hogaboam CM, Simpson KJ, Chensue SW, Steinhauser ML < Lukacs NW, Gauldie J, et al. Macrophage inflammatory protein-2 gene therapy attenuates adenovirus- and acetaminophen-mediated hepatic injury. Gene Ther 1999;6:573-584.
27. Tinel M, Berson A, Vadrot N, Descatoire V, Grodet A, Feldman G, et al. Subliminal Fas stimulation increases the hepatotoxicity of acetaminophen and bromobenzene in mice. HEPATOLOGY 2004;39:655-666.